ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

ESMO BC Global Perspective | Professor Sung-Bae Kim: Rethinking Treatment for Intermediate-Risk HR+ Early Breast Cancer—Could Adjuvant CDK4/6 Inhibitors Replace Chemotherapy?

During the “Adjuvant Therapy for Hormone Receptor-Positive Early Breast Cancer” session at the 2026 ESMO Breast Cancer Congress (ESMO BC), Professor Sung-Bae Kim from Asan Medical Center, University of Ulsan College of Medicine, delivered an insightful presentation entitled “Adjuvant CDK4/6 Inhibitors: Could They Replace Chemotherapy for Intermediate-Risk ER+ Early Breast Cancer?” Following the session, Professor Sung-Bae Kim spoke with Oncology Frontier and further elaborated on the key concepts presented in his talk.
Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role of ctDNA Monitoring in ER+ Early Breast Cancer: Could It Change Practice?”
Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou, Zhejiang Province. Hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, the event brought together top-tier colorectal surgery experts from across China for in-depth discussions on key topics, including colorectal cancer liver metastasis, peritoneal metastasis, para-aortic lymph node metastasis, locally advanced rectal cancer, combined organ resection, and the association between obesity and colorectal cancer. Prof. Toh Han Chong from the National Cancer Centre Singapore (NCCS) attended the conference.
Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment

Professor Qinlong Zheng: Focusing on Clonal Evolution to Optimize Hematologic Malignancy Diagnosis and Treatment

To further advance scientific research and clinical practice in hematologic malignancies in China and establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical experience, and future directions in the discipline, creating a professional event with high academic value, strong clinical relevance, and broad industry influence.
Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

Professor Gao Zifen: Breakthroughs and Future Directions in Hematologic Malignancy Diagnostics — From Integrated to Precision Medicine | 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish an authoritative academic exchange platform for the field, the 2026 Boren Hematologic Malignancies Precision Diagnosis and Treatment Conference, jointly organized by the Beijing Association for the Promotion of Integrated Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering, was officially held in Beijing on May 16 in a hybrid online-offline format. The conference brought together leading experts and scholars in hematologic malignancies from across the country, focusing on cutting-edge technologies, clinical diagnostic and treatment experience, and future directions in the discipline, creating a professional event of high academic caliber, strong clinical relevance, and significant industry influence.
Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference

Professor Tong Chunrong: Entering a New Era of Integrated and Precision Diagnosis and Treatment in Hematologic Malignancies | 2026 Boren Precision Hematologic Oncology Conference

To further advance scientific research and clinical practice in hematologic malignancies in China and to establish a high-level academic exchange platform, the 2026 Boren Precision Hematologic Oncology Conference officially opened in Beijing on May 16 in a hybrid online-offline format. The conference was jointly hosted by the Beijing Association for the Promotion of Integrated Traditional Chinese and Western Medicine in Chronic Disease Prevention and the Beijing Society of Bioengineering.
Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

On April 21, 2026, Professor Shi Yanxia and Professor An Xin’s team from Sun Yat-sen University Cancer Center published their latest findings in the international journal Cancer Communications under the title “Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.”
“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice: